Luo Jinli, Zhou Ling, Sun Aru, Min Ye, Lin Yiqun, Han Lin
Institute of Metabolic Diseases, Guang' Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Graduate College, Beijing University of Chinese Medicine, Beijing, 100029, China.
Heliyon. 2024 Jul 31;10(16):e35114. doi: 10.1016/j.heliyon.2024.e35114. eCollection 2024 Aug 30.
Vitamin D (VD), selenium preparations (Se), and thyroid hormone replacement therapy are commonly used to treat Hashimoto thyroiditis (HT). Increasing evidence suggests that traditional Chinese medicine (TCM) is an effective therapeutic strategy in the treatment of HT.
This study aimed to investigate the efficacy and safety of commonly-used drugs for HT.
A literature search was performed using PubMed, Web of Science, Cochrane Library, EMBASE, Chinese China National Knowledge Infrastructure (CNKI), Clinical Trial Registry (Chi CTR), China Science and Technology Journal Database (the VIP), Wanfang Database, and China Chinese Biomedical Database (CBM) from January 1, 2003, to December 31, 2022. The outcomes included TPOAb, TgAb, TSH, FT3, FT4, and adverse events. Our study was registered in PROSPERO (CRD42023449705).
Sixty trials and 4719 participants were included, comparing 16 treatments: VD, Se, LT-4, Se + LT-4, HM, placebo + LT-4, HM + LT-4, Se + myolnositol, Se + VD, HM + Se, mannan peptide, LT-4+prednisone, Methimazole, Methimazole + HM, Tapazole + Propranolol, and placebo. We found that Chinese herbal medicine has significant effect . LT-4 [MD 0.10, 95 % confidence interval 0.02 to 0.50]) and LT-4+placebo [MD 0.10, 95 % confidence interval 0.01 to 0.77]) in reducing TPOAb. Although receiving LT-4+prednisone was not statistically significant, the treatment ranking showed that this combination therapy had the highest probability of reducing TPOAb levels (72.8 %). In addition, the effect of Se plus LT-4 was not statistically significant; however, the treatment ranking showed that this combination therapy had the highest probability (78.6 %) of reducing TgAb levels, followed by HM (64.0 %). Reports on side effects have mainly focused on the digestive and cardiovascular systems.
Our analyses showed that HM alone or in combination with other treatments for patients with HT can improve the side effects of other drugs, enhance efficacy, and maybe the most effective option for treating HT. However, there still need further verified using high-quality evidence.
维生素D(VD)、硒制剂(Se)和甲状腺激素替代疗法常用于治疗桥本甲状腺炎(HT)。越来越多的证据表明,传统中药(TCM)是治疗HT的一种有效治疗策略。
本研究旨在调查常用药物治疗HT的疗效和安全性。
使用PubMed、科学网、考克兰图书馆、EMBASE、中国知网(CNKI)、临床试验注册中心(中国临床试验注册中心)、维普资讯、万方数据库和中国生物医学文献数据库(CBM),对2003年1月1日至2022年12月31日期间的文献进行检索。观察指标包括甲状腺过氧化物酶抗体(TPOAb)、甲状腺球蛋白抗体(TgAb)、促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)和不良事件。本研究已在国际前瞻性注册平台(PROSPERO)注册(注册号:CRD42023449705)。
纳入60项试验,共4719名参与者,比较了16种治疗方法:VD、Se、左甲状腺素(LT-4)、Se+LT-4、中药、安慰剂+LT-4、中药+LT-4、Se+肌醇、Se+VD、中药+Se、甘露聚糖肽、LT-4+泼尼松、甲巯咪唑、甲巯咪唑+中药、他巴唑+普萘洛尔和安慰剂。我们发现中药具有显著疗效。LT-4[平均差(MD)0.10,95%置信区间0.02至0.50])和LT-4+安慰剂[MD 0.10,95%置信区间0.01至0.77])在降低TPOAb方面有效果。虽然接受LT-4+泼尼松治疗无统计学意义,但治疗排名显示这种联合治疗降低TPOAb水平的概率最高(72.8%)。此外,Se加LT-4的效果无统计学意义;然而,治疗排名显示这种联合治疗降低TgAb水平的概率最高(78.6%),其次是中药(64.0%)。关于副作用的报告主要集中在消化系统和心血管系统。
我们的分析表明,单独使用中药或与其他治疗方法联合用于HT患者,可以改善其他药物的副作用,提高疗效,可能是治疗HT最有效的选择。然而,仍需要高质量证据进一步验证。